GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Cyclically Adjusted Book per Share

Syndax Pharmaceuticals (STU:1T3) Cyclically Adjusted Book per Share : €1.90 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Syndax Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2024 was €4.745. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.90 for the trailing ten years ended in Jun. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-09-21), Syndax Pharmaceuticals's current stock price is €16.40. Syndax Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was €1.90. Syndax Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 8.63.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Syndax Pharmaceuticals was 12.12. The lowest was 9.04. And the median was 10.18.


Syndax Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Syndax Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Cyclically Adjusted Book per Share Chart

Syndax Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.42 0.80

Syndax Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 0.01 0.80 0.97 1.90

Competitive Comparison of Syndax Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Syndax Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Syndax Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Syndax Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book= Book Value per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=4.745/132.5538*132.5538
=4.745

Current CPI (Jun. 2024) = 132.5538.

Syndax Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201409 -18.108 100.428 -23.901
201412 -19.509 99.070 -26.103
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 -12.928 100.392 -17.070
201512 -13.720 99.792 -18.224
201603 5.754 100.470 7.591
201606 5.321 101.688 6.936
201609 4.599 101.861 5.985
201612 4.379 101.863 5.698
201703 3.721 102.862 4.795
201706 4.379 103.349 5.616
201709 3.637 104.136 4.630
201712 3.614 104.011 4.606
201803 2.855 105.290 3.594
201806 2.652 106.317 3.306
201809 2.290 106.507 2.850
201812 1.877 105.998 2.347
201903 2.241 107.251 2.770
201906 1.804 108.070 2.213
201909 1.473 108.329 1.802
201912 1.048 108.420 1.281
202003 1.601 108.902 1.949
202006 3.404 108.767 4.148
202009 2.885 109.815 3.482
202012 4.329 109.897 5.221
202103 3.973 111.754 4.712
202106 3.663 114.631 4.236
202109 3.463 115.734 3.966
202112 6.573 117.630 7.407
202203 6.180 121.301 6.753
202206 6.071 125.017 6.437
202209 5.680 125.227 6.012
202212 6.479 125.222 6.858
202303 5.939 127.348 6.182
202306 5.318 128.729 5.476
202309 4.833 129.860 4.933
202312 5.991 129.419 6.136
202403 5.325 131.776 5.356
202406 4.745 132.554 4.745

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Syndax Pharmaceuticals  (STU:1T3) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Syndax Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=16.40/1.9
=8.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Syndax Pharmaceuticals was 12.12. The lowest was 9.04. And the median was 10.18.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Syndax Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Syndax Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
35 Gatehouse Drive, Building D, Floor 3, Waltham, MA, USA, 02451
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Syndax Pharmaceuticals Headlines

No Headlines